APA (7th ed.) Citation

Drescher, C., Moore, K., Liu, J., O’Malley, D., Wang, E., Wang, J., . . . Youssoufian, H. (2018). Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer. Annals of oncology, 29, viii412-viii413. https://doi.org/10.1093/annonc/mdy288.031

Chicago Style (17th ed.) Citation

Drescher, C., et al. "Phase I/II, Open-label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects with Relapsed/refractory Cervical Cancer." Annals of Oncology 29 (2018): viii412-viii413. https://doi.org/10.1093/annonc/mdy288.031.

MLA (9th ed.) Citation

Drescher, C., et al. "Phase I/II, Open-label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects with Relapsed/refractory Cervical Cancer." Annals of Oncology, vol. 29, 2018, pp. viii412-viii413, https://doi.org/10.1093/annonc/mdy288.031.